Literature DB >> 16572895

Modulation of vascular endothelium by imatinib: a study on the EA.hy 926 endothelial cell line.

T Vrekoussis1, E N Stathopoulos, U De Giorgi, M Kafousi, K Pavlaki, A Kalogeraki, E Chrysos, G Fiorentini, O Zoras.   

Abstract

In this study the EA.hy 926 endothelial cell line--simulating endothelial cells--was treated with imatinib in order to define a possible anti-angiogenic role for imatinib. Dose and time response experiments were performed. Cell morphology was studied, while migration efficiency, intercellular permeability and VE-cadherin expression were assayed, both in the presence and in the absence of imatinib. Imatinib-induced EA.hy 926 cell apoptosis was also examined. Results showed that imatinib reduced the endothelial cell population, changed cell monolayer morphology and reduced cell-to-cell cohesiveness. Migration efficiency was significantly decreased while intercellular permeability was 2.76-fold increased in the presence of imatinib. Indirect immunofluorescence microscopy showed nearly complete down-regulation of VE cadherin in imatinib-treated cells. Furthermore, apoptotic activity was detected in imatinib-treated cells. Altogether our results support an antiangiogenic profile for imatinib that possibly contributes to its therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16572895     DOI: 10.1179/joc.2006.18.1.56

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  6 in total

1.  VE-cadherin Regulates Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Sensitivity to Apoptosis.

Authors:  Heather O'Leary; Stephen M Akers; Debra Piktel; Cheryl Walton; James E Fortney; Karen H Martin; Michael Craig; James Coad; Laura F Gibson
Journal:  Cancer Microenviron       Date:  2010-03-02

2.  The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study.

Authors:  Hélène Haguet; Céline Bouvy; Anne-Sophie Delvigne; Elise Modaffari; Adeline Wannez; Pierre Sonveaux; Jean-Michel Dogné; Jonathan Douxfils
Journal:  Front Pharmacol       Date:  2020-07-03       Impact factor: 5.810

3.  The effect of piperlongumine on endothelial and lung adenocarcinoma cells with regulated expression of profilin-1.

Authors:  Maciej Gagat; Marta Hałas-Wiśniewska; Wioletta Zielińska; Magdalena Izdebska; Dariusz Grzanka; Alina Grzanka
Journal:  Onco Targets Ther       Date:  2018-11-22       Impact factor: 4.147

4.  Diuretic-Resistant Ascites Following Laparoscopic Surgery in a Patient With Chronic Myeloid Leukemia on Imatinib Therapy.

Authors:  Efthymia Pappa; Marina Gkeka; Ifigeneia Kiki; Pagona Gourna; Constantinos Christopoulos
Journal:  Cureus       Date:  2021-02-04

5.  Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis.

Authors:  Megan Perkins; Beatrice M Girard; Susan E Campbell; Grant W Hennig; Margaret A Vizzard
Journal:  Front Syst Neurosci       Date:  2022-04-22

6.  Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo.

Authors:  Paulius Venalis; Britta Maurer; Alfiya Akhmetshina; Nicole Busch; Clara Dees; Michael Stürzl; Jochen Zwerina; Astrid Jüngel; Steffen Gay; Georg Schett; Oliver Distler; Jörg H W Distler
Journal:  J Cell Mol Med       Date:  2009-10       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.